Literature DB >> 18941910

Automated CT-based analysis to detect changes in the prevalence of lytic bone metastases from breast cancer.

T Skrinskas1, M Clemons, O Freedman, I Weller, C M Whyne.   

Abstract

The spinal column is the most frequent site of bone metastasis in patients with breast cancer. It is important to understand how the pattern of vertebral lesions may be affected by the introduction of modern cancer therapies. The purpose of this study was to characterize changes in the radiological appearance of spinal column metastases over the past decade using highly automated Computed Tomography (CT) based computational analysis methods. Two case series studies were performed using CT scans of patients with confirmed spinal metastases secondary to breast cancer: Cohort A with CT scans acquired between 1998 and 2001 and Cohort B with CT scans acquired between 2004 and 2007. Diseased vertebrae were classified as lytic, blastic, or mixed based on CT scan intensity through an automated 3D computer algorithm. The relative incidence of lytic vertebral metastases decreased in comparing Cohort B to Cohort A (12% vs. 49%) with a corresponding increase in mixed lesions (51% vs. 18%) Significant associations were found between the percentage of lytic lesions in number of diseased vertebrae measured per patient and lack of bisphosphonate use (RR = 2.6) and for membership in Cohort A vs. Cohort B (RR = 5.9). This work highlights a change in the CT appearance of vertebral metastases from breast cancer during the past decade toward a lower proportion of lytic disease. Observation of patient therapies suggests that differences in radiological assessment may be linked, at least in part, to bisphosphonate use. These findings have important implications for both clinical practice and research strategies involving vertebral metastases.

Entities:  

Mesh:

Year:  2008        PMID: 18941910     DOI: 10.1007/s10585-008-9219-6

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  23 in total

1.  Quantitative characterization of metastatic disease in the spine. Part I. Semiautomated segmentation using atlas-based deformable registration and the level set method.

Authors:  M Hardisty; L Gordon; P Agarwal; T Skrinskas; C Whyne
Journal:  Med Phys       Date:  2007-08       Impact factor: 4.071

2.  The significance of the site of recurrence to subsequent breast cancer survival.

Authors:  A Imkampe; S Bendall; T Bates
Journal:  Eur J Surg Oncol       Date:  2006-10-16       Impact factor: 4.424

3.  [Bioclinical correlations in bony metastases. Results of a prospective study. 60 cases].

Authors:  Raja Belhaj; Hamouda Boussen; Abderraouf Ghanem; Saloua Essafer; Latifa Harzallah; Farhat Ben Ayed; Fethi Guemira
Journal:  Tunis Med       Date:  2002-11

Review 4.  Bisphosphonates for breast cancer.

Authors:  N Pavlakis; Rl Schmidt; M Stockler
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

5.  Quantitative characterization of metastatic disease in the spine. Part II. Histogram-based analyses.

Authors:  Carl Whyne; Michael Hardisty; Florence Wu; Tomas Skrinskas; Mark Clemons; Lyle Gordon; Parminder S Basran
Journal:  Med Phys       Date:  2007-08       Impact factor: 4.071

6.  American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.

Authors:  B E Hillner; J N Ingle; J R Berenson; N A Janjan; K S Albain; A Lipton; G Yee; J S Biermann; R T Chlebowski; D G Pfister
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

Review 7.  Osteolytic bone metastasis in breast cancer.

Authors:  T Yoneda; A Sasaki; G R Mundy
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

8.  Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy.

Authors:  V Scheid; A U Buzdar; T L Smith; G N Hortobagyi
Journal:  Cancer       Date:  1986-12-15       Impact factor: 6.860

9.  Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.

Authors:  Lee S Rosen; David H Gordon; William Dugan; Pierre Major; Peter D Eisenberg; Louise Provencher; Mary Kaminski; Joe Simeone; John Seaman; Bee-Lian Chen; Robert E Coleman
Journal:  Cancer       Date:  2004-01-01       Impact factor: 6.860

10.  Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions.

Authors:  C C Quattrocchi; S Piciucchi; M Sammarra; D Santini; B Vincenzi; G Tonini; R F Grasso; B B Zobel
Journal:  Radiol Med       Date:  2007-10-21       Impact factor: 6.313

View more
  5 in total

1.  Mixed spine metastasis detection through positron emission tomography/computed tomography synthesis and multiclassifier.

Authors:  Jianhua Yao; Joseph E Burns; Vic Sanoria; Ronald M Summers
Journal:  J Med Imaging (Bellingham)       Date:  2017-06-05

2.  Cortical shell unwrapping for vertebral body abnormality detection on computed tomography.

Authors:  Jianhua Yao; Joseph E Burns; Hector Muñoz; Ronald M Summers
Journal:  Comput Med Imaging Graph       Date:  2014-04-13       Impact factor: 4.790

3.  The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.

Authors:  Allan Lipton; Robert Uzzo; Robert J Amato; Georgiana K Ellis; Behrooz Hakimian; G David Roodman; Matthew R Smith
Journal:  J Natl Compr Canc Netw       Date:  2009-10       Impact factor: 11.908

4.  Influence of Hormone Receptor Status on Spinal Metastatic Lesions in Patients with Breast Cancer.

Authors:  Jenny Lin; Leanne Goldstein; Amanda Nesbit; Mike Y Chen
Journal:  World Neurosurg       Date:  2015-08-07       Impact factor: 2.104

Review 5.  Biomechanical Properties of Metastatically Involved Osteolytic Bone.

Authors:  Cari M Whyne; Dallis Ferguson; Allison Clement; Mohammedayaz Rangrez; Michael Hardisty
Journal:  Curr Osteoporos Rep       Date:  2020-10-19       Impact factor: 5.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.